We are live on ! Find out more
LOGC

LogicBio Therapeutics, Inc. Common Stock
LOGC

Delisted

LOGC was delisted on the 15th of November, 2022.

Back to rankings

57 hedge funds and large institutions have $73.2M invested in LogicBio Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 19 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more capital invested

Capital invested by funds: $69.8M → $73.2M (+$3.45M)

10% less funds holding

Funds holding: 63 → 57 (-6)

47% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 19

55% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 11

75% less call options, than puts

Call options by funds: $14K | Put options by funds: $57K

Holders
57
Holders Change
-6
Holders Change %
-9.52%
% of All Funds
1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
10
Reduced
19
Closed
11
Calls
$14K
Puts
$57K
Net Calls
-$43K
Net Calls Change
-$41K

Top Buyers

Rank Fund Capital Flow
1
EP
Eversept Partners
New York
+$1.54M
2
PIM
Platinum Investment Management
Australia
+$1.41M
3
BCM
Bridgeway Capital Management
Texas
+$440K
4
SC
Samlyn Capital
New York
+$236K
5
SFM
Sphera Funds Management
Israel
+$106K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$811K
2
Verition Fund Management
Verition Fund Management
Connecticut
-$416K
3
TEE
Tibra Equities Europe
United Kingdom
-$340K
4
JP Morgan Chase
JP Morgan Chase
New York
-$254K
5
Renaissance Technologies
Renaissance Technologies
New York
-$217K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$38.8M – – –
Franklin Resources
2
Franklin Resources
California
$7.32M – – –
SC
3
Samlyn Capital
New York
$6.75M +$236K +53,656 +4%
Vanguard Group
4
Vanguard Group
Pennsylvania
$3.35M +$65K +14,790 +2%
LPC
5
Lion Point Capital
New York
$2.29M – – –
BBA
6
Baker Bros. Advisors
New York
$2.07M – – –
EP
7
Eversept Partners
New York
$1.6M +$1.54M +349,919 New
PIM
8
Platinum Investment Management
Australia
$1.47M +$1.41M +320,273 New
Fidelity Investments
9
Fidelity Investments
Massachusetts
$1.45M -$811K -184,500 -37%
PVI
10
Pura Vida Investments
New York
$1.12M -$16.6K -3,764 -2%
BlackRock
11
BlackRock
New York
$988K -$23.8K -5,412 -2%
SCM
12
Sio Capital Management
New York
$836K – – –
BCM
13
Bridgeway Capital Management
Texas
$808K +$440K +100,000 +131%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$634K +$27.9K +6,344 +5%
Verition Fund Management
15
Verition Fund Management
Connecticut
$520K -$416K -94,567 -45%
E
16
Ergoteles
New York
$301K -$4.2K -956 -1%
UBS Group
17
UBS Group
Switzerland
$286K -$11.4K -2,601 -4%
Millennium Management
18
Millennium Management
New York
$222K -$201K -45,755 -49%
Renaissance Technologies
19
Renaissance Technologies
New York
$216K -$217K -49,300 -51%
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$211K +$78.2K +17,791 +63%
Goldman Sachs
21
Goldman Sachs
New York
$193K -$56.5K -12,844 -23%
HF
22
HRT Financial
New York
$192K -$14.6K -3,323 -7%
Marshall Wace
23
Marshall Wace
United Kingdom
$181K -$4.6K -1,045 -3%
FT
24
Fiduciary Trust
Massachusetts
$174K – – –
SMH
25
Sanders Morris Harris
Texas
$160K +$88K +20,000 +133%
1
2 3

LOGC Hedge Fund Activity: Q3 2021 in Review

57 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q3 2021, worth a combined $73.2M — up 4.9% from $69.8M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of LOGC and 5 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 10 added.

The largest buyer was Eversept Partners, opening a new position worth an estimated $1.54M. The largest seller was Fidelity Investments, cutting an estimated $811K.

  • 57 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q3 2021, down from 63 in Q2 2021.
  • Funds reported $73.2M of LogicBio Therapeutics, Inc. Common Stock stock for Q3 2021, up 4.9% quarter-over-quarter.
  • 5 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q3 2021 and 11 closed out, a net change of -6 holders.
  • The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q3 2021 was Eversept Partners, an estimated $1.54M added.
  • The largest LogicBio Therapeutics, Inc. Common Stock seller in Q3 2021 was Fidelity Investments, an estimated $811K sold.

Based on aggregated 13F filings for Q3 2021.